Last reviewed 2026-04-23 · How we verify

DE-089 ophthalmic solution

DE-089 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.

DE-089 ophthalmic solution is a corticosteroid used to treat inflammation in the eye. Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye, Treatment of non-infectious keratitis and anterior uveitis.

At a glance

Mechanism of action

It works by suppressing the immune system's response to reduce inflammation and swelling in the eye. Corticosteroids like DE-089 are commonly used to treat conditions such as uveitis and conjunctivitis.

Approved indications

• Treatment of non-infectious uveitis affecting the posterior segment of the eye
• Treatment of non-infectious keratitis and anterior uveitis

Common side effects

• Increased intraocular pressure
• Cataract
• Glaucoma

Key clinical trials

• Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease (PHASE1)
• Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (PHASE2)
• Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (PHASE3)
• Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• DE-089 ophthalmic solution CI brief — competitive landscape report
• DE-089 ophthalmic solution updates RSS · CI watch RSS
• Santen Pharmaceutical Co., Ltd. portfolio CI